Harmony Asset Management LLC Boosts Holdings in AbbVie Inc. $ABBV

Harmony Asset Management LLC boosted its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 134.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 22,863 shares of the company's stock after acquiring an additional 13,094 shares during the period. AbbVie accounts for about 1.5% of Harmony Asset Management LLC's holdings, making the stock its 16th biggest position. Harmony Asset Management LLC's holdings in AbbVie were worth $5,753,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABBV. Blackhawk Capital Partners LLC increased its stake in shares of AbbVie by 5.6% during the 2nd quarter. Blackhawk Capital Partners LLC now owns 11,393 shares of the company's stock worth $2,867,000 after purchasing an additional 600 shares during the last quarter. Mission Wealth Management LP lifted its stake in AbbVie by 119.1% in the second quarter. Mission Wealth Management LP now owns 69,052 shares of the company's stock valued at $17,376,000 after purchasing an additional 37,531 shares during the last quarter. Walled Lake Planning & Wealth Management LLC grew its holdings in AbbVie by 7.8% during the second quarter. Walled Lake Planning & Wealth Management LLC now owns 3,250 shares of the company's stock valued at $818,000 after purchasing an additional 236 shares during the period. Hughes Financial Services LLC increased its position in AbbVie by 14.9% in the second quarter. Hughes Financial Services LLC now owns 654 shares of the company's stock worth $165,000 after buying an additional 85 shares during the last quarter. Finally, Alpha Zero LLC purchased a new position in shares of AbbVie during the 2nd quarter valued at $250,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Price Performance

ABBV opened at $249.12 on Thursday. The company has a fifty day moving average price of $243.99 and a 200-day moving average price of $225.73. The firm has a market capitalization of $440.14 billion, a P/E ratio of 70.37, a price-to-earnings-growth ratio of 0.83 and a beta of 0.30. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analysts' expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business's quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts expect that AbbVie Inc. will post 14.07 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. AbbVie's dividend payout ratio (DPR) is presently 195.48%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ABBV shares. Bank of America boosted their price objective on AbbVie from $234.00 to $276.00 and gave the company a "buy" rating in a research note on Friday, July 10th. BNP Paribas Exane boosted their target price on shares of AbbVie from $218.00 to $247.00 and gave the company a "neutral" rating in a report on Tuesday. HSBC reaffirmed a "buy" rating and issued a $300.00 price target on shares of AbbVie in a report on Monday, July 6th. Sanford C. Bernstein reissued a "market perform" rating on shares of AbbVie in a report on Tuesday, June 23rd. Finally, Evercore set a $235.00 target price on AbbVie in a research note on Friday, May 15th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, AbbVie currently has an average rating of "Moderate Buy" and an average price target of $274.33.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Canada supports UBRELVY reimbursement: Canada’s Drug Agency recommended reimbursement of UBRELVY for acute migraine treatment in adults. The decision could improve access and provide another growth opportunity for AbbVie’s neuroscience portfolio. AbbVie Wins Canada Reimbursement Backing for Adult Migraine Treatment
• Positive Sentiment: BOTOX regulatory progress: AbbVie’s BOTOX filing helped attract investor attention, adding potential support for the aesthetics business and contributing to the stock’s recent strength. AbbVie Gains on Botox Filing
• Positive Sentiment: Immunology remains the key growth engine: Skyrizi and Rinvoq delivered strong sales, market-share gains and contributions from new indications, helping drive AbbVie’s second-quarter growth. Recent results also exceeded consensus estimates for earnings and revenue. How Much Did Immunology Drugs Contribute to AbbVie’s Q2 Performance?
• Neutral Sentiment: Pipeline updates provide optionality but limited immediate impact: AbbVie completed early testing of a venetoclax combination in high-risk myelodysplastic syndromes and completed a Phase 3 BOTOX jawline study. The updates advance development, but the reports did not provide definitive clinical results. AbbVie’s Venetoclax Combo in High-Risk MDS
• Neutral Sentiment: Analyst target increase reflects limited near-term upside: BNP Paribas Exane raised its price target from $218 to $247 while retaining a neutral rating, implying the shares were slightly above its revised valuation. Erste Group also modestly reduced its FY2027 EPS forecast but kept a Buy rating. BNP Paribas Exane AbbVie Price Target
• Negative Sentiment: Apogee acquisition increases leverage: Shareholders approved AbbVie’s Apogee Therapeutics acquisition, expanding the pipeline but requiring roughly $8 billion of additional debt. Investors focused on dividend safety may view the higher leverage and execution risk negatively. AbbVie Piles on $8 Billion in Debt for Its Apogee Deal

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source